Cargando…

Dysregulation of T(FH)-B-T(RM) lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer

Patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations exhibit an unfavorable response to PD-1 inhibitor through unclear mechanisms. Hypothesizing that EGFR mutations alter tumor-immune interactions, we compare tumor-infiltrating lymphocytes between E...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Jae-Won, Park, Seyeon, Kim, Gamin, Han, Heonjong, Shim, Hyo Sup, Shin, Sunhye, Bae, Yong-Soo, Park, Seong Yong, Ha, Sang-Jun, Lee, Insuk, Kim, Hye Ryun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523541/
https://www.ncbi.nlm.nih.gov/pubmed/34663810
http://dx.doi.org/10.1038/s41467-021-26362-0
Descripción
Sumario:Patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations exhibit an unfavorable response to PD-1 inhibitor through unclear mechanisms. Hypothesizing that EGFR mutations alter tumor-immune interactions, we compare tumor-infiltrating lymphocytes between EGFR mutant (EGFR-MT) and wild type (EGFR-WT) tumors through single-cell transcriptomic analysis. We find that B cells, CXCL13-producing follicular helper CD4(+) T (T(FH))-like cells, and tissue-resident memory CD8(+) T (T(RM))-like cells decreased in EGFR-MT tumors. The NOTCH-RBPJ regulatory network, which is vital for persistence of T(RM) state, is perturbed, and the interactions between T(FH) and B cells through the CXCL13-CXCR5 axis disappear in EGFR-MT tumors. Notably, the proportion of T(RM)-like cells is predictive for anti-PD-1 response in NSCLC. Our findings suggest that the impairment of T(FH)-B-T(RM) cooperation in tertiary lymphoid structure formation, accompanied by the dysregulation of T(RM) homeostasis and the loss of T(FH)-B crosstalk, underlies unfavorable anti-PD-1 response in EGFR-MT lung tumors.